Free tool
FAERS Monitor: Qulipta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215206 or its brand name (Qulipta, Atogepant). Reports on generic versions are filed under their own applications.
Reports
6,969
Serious
2,589
37% of reports
Hospitalization
663
Death reported
83
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- migraine1,224
- drug ineffective829
- headache672
- nausea639
- constipation474
- fatigue446
- dizziness276
- therapy interrupted201
- pain189
- vomiting188
- off label use184
- decreased appetite182
- weight decreased165
- anxiety159
- therapeutic product effect incomplete154
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 3 |
| 2020 | 8 |
| 2021 | 28 |
| 2022 | 1,687 |
| 2023 | 1,716 |
| 2024 | 999 |
| 2025 | 1,371 |
| 2026 | 1,155 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,190 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| migraineSignal | 1,224 | 39.2 | 37.2 | 45,131 |
| therapy interruptedSignal | 201 | 8.5 | 7.4 | 1,325 |
| constipationSignal | 474 | 6.6 | 6.0 | 2,252 |
| therapeutic product effect incompleteSignal | 154 | 6.5 | 5.6 | 719 |
| headacheSignal | 672 | 3.2 | 3.0 | 1,068 |
| nauseaSignal | 639 | 2.4 | 2.3 | 561 |
| decreased appetiteSignal | 182 | 2.4 | 2.0 | 144 |
| drug ineffective | 829 | 1.9 | 1.8 | 375 |
| weight decreased | 165 | 1.8 | 1.5 | 57 |
| fatigue | 446 | 1.7 | 1.6 | 142 |
| anxiety | 159 | 1.7 | 1.4 | 44 |
| dizziness | 276 | 1.7 | 1.5 | 75 |
| vomiting | 188 | 1.2 | 1.0 | 7 |
| pain | 189 | 0.9 | 0.8 | 1 |
| off label use | 184 | 0.6 | 0.5 | 40 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.